This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other Osteochondrodysplasia with Tubular Bone/Spine Growth Defects기타 골연골형성이상 (기타골연골형성이상)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q77.8 (other osteochondrodysplasias) | Special Copayment Reduction: V228 (rare disease)
B. SynonymsOther osteochondrodysplasia with defects of growth of tubular bones and spine, Acromesomelic dysplasia
C. Adult onsetLikelihood of first onset in adulthood very low — most are diagnosed at birth or in childhood. Joint complications may progress in adults as well.
1. HistoryAcromesomelic dysplasia: described by Maroteaux in 1971. The ICD Q77.8 group is a residual category of osteochondrodysplasias with defects of growth of tubular bones and spine not covered by Q77.4–7.
2. CausesHeterogeneous group. Acromesomelic dysplasia: BMPR1B (Grebe type, AR), NPR2 (Maroteaux type, AR), GDF5 (Hunter-Thompson type, AR), etc. Variants in genes of various signaling pathways.
3. GeneticsGrebe dysplasia: BMPR1B (20q13.2, AR). Maroteaux dysplasia: NPR2 (9p21, AR). Hunter-Thompson: GDF5 (20q11.2, AR). Mostly autosomal recessive.
4. General epidemiologyEach subtype very rare (1 in several hundred thousand to several million births). Most ultra-rare. Increased frequency in certain founder populations.
5. PathophysiologyAbnormality of the BMP/GDF signaling pathway (regulating chondrocyte differentiation). Abnormality of the NPR2 pathway (CNP signaling). Subtype-specific abnormalities of the related pathways result in growth plate dysfunction of the distal long bones.
6. SymptomsAcromesomelic or mesomelic limb shortening, brachydactyly, joint dysplasia, spinal abnormalities. Large differences between subtypes.
7. SignsShort distal limbs, joint contractures, radiographic shortening and malformation of the distal long bones, spinal abnormalities (depending on subtype). Extreme distal shortening in the Grebe type.
8. ScreeningPrenatal ultrasound (distal limb shortening, shortened fingers and toes). Molecular genetic prenatal diagnosis in high-risk families. NGS panel when clinically suspected.
9. DiagnosisClinical and radiographic findings + NGS-based skeletal dysplasia panel or single-gene analysis. Confirmation of the gene of each subtype (BMPR1B, NPR2, GDF5, etc.).
10. TreatmentNo curative treatment. Limb lengthening, correction of joint contractures, physical therapy, orthoses, pain management. NPR2-related type: vosoritide under investigation.
11. PrognosisNormal life expectancy possible. Functional limitation and chronic pain are the main factors reducing quality of life. Normal intelligence.
12. PreventionGenetic counseling, preimplantation genetic testing (PGT), prenatal diagnosis. Regular follow-up to prevent complications.
13. ReferencesMaroteaux P et al. Sem Hop Paris 1971; Thomas JT et al. Nat Genet 1996; Bartels CF et al. Am J Hum Genet 2004 … and 7 more

1. History

The ICD-10 code Q77.8 is a residual category covering 'other osteochondrodysplasia with defects of growth of tubular bones and spine,' and includes skeletal growth disorders not explicitly classified under Q77.4 (achondroplasia) to Q77.7 (spondyloepiphyseal dysplasia). The best-defined disease group in this category is Acromesomelic Dysplasia (AMD), a group of rare skeletal dysplasias characterized by selective shortening of the distal (acral) and middle (mesomelic) limb segments.

The concept of acromesomelic dysplasia was formalized in 1971 when Pierre Maroteaux of France and colleagues first described it under the name 'acromesomelic dwarfism.' Several clinically distinct subtypes were subsequently reported, and each was found to have a different causative gene.

Looking at the history of the major acromesomelic dysplasia subtypes, Grebe chondrodysplasia, reported in Brazil, originated with Grebe's description in 1952 of unusual cases of distal limb hypoplasia. In 1996, Thomas et al. proposed GDF5 gene variants as the cause of Grebe dysplasia, and in 2004 Bartels et al. identified BMPR1B variants as a cause of Grebe dysplasia and a similar phenotype (Hunter-Thompson dysplasia). Maroteaux dysplasia (acromesomelic dysplasia, Maroteaux type) is a mild acromesomelic dysplasia described by Maroteaux, and in 2004 variants in the NPR2 (natriuretic peptide receptor 2) gene were identified as its cause. NPR2 is the receptor for CNP (C-type natriuretic peptide) and is the same protein as NPR-B, the target of vosoritide, a treatment for achondroplasia. This suggests an interesting pathogenetic link whereby abnormalities at different levels of the same CNP-NPR2 signaling pathway cause achondroplasia (reduced CNP signaling due to FGFR3 overactivation) and Maroteaux dysplasia (reduced CNP signaling due to NPR2 loss of function), respectively.

Acromesomelic dysplasias are currently divided into dysplasias related to the BMP/GDF signaling pathway (Grebe, Hunter-Thompson, DuPan syndrome, etc.) and dysplasias related to the CNP/NPR2 signaling pathway (Maroteaux dysplasia), which suggests different causative genes and different potential therapeutic approaches for each.


2. Causes

Because the Q77.8 category includes a heterogeneous group of genetic disorders, the causative genes and mechanisms differ for each subtype. The causes are described with a focus on the most important subtype, acromesomelic dysplasia.

Grebe chondrodysplasia: caused by homozygous or compound heterozygous pathogenic variants in the BMPR1B (Bone Morphogenetic Protein Receptor 1B) gene (20q13.2). BMPR1B is a BMP (Bone Morphogenetic Protein) receptor that mediates signal transduction of BMP-family ligands, including GDF5 (Growth Differentiation Factor 5), and regulates chondrocyte proliferation and differentiation. Loss of BMPR1B function blocks BMP signaling to chondrocytes of the distal cartilage plates (growth plates), so that growth of the distal limb segments is extremely suppressed. Inheritance is autosomal recessive; heterozygous carriers are asymptomatic or may show mild brachydactyly (brachydactyly A2).

Hunter-Thompson dysplasia: caused by variants in the GDF5 (Growth Differentiation Factor 5) gene (20q11.2) or BMPR1B, and overlaps clinically in part with Grebe dysplasia. GDF5 variants show a gene dosage–phenotype correlation: heterozygous variants cause brachydactyly (brachydactyly C), and homozygous variants cause a more severe phenotype (resembling Hunter-Thompson or Grebe dysplasia).

Acromesomelic dysplasia, Maroteaux type (AMDM): caused by homozygous or compound heterozygous loss-of-function variants in the NPR2 (Natriuretic Peptide Receptor 2) gene (9p21). NPR2 (NPR-B) is the receptor for CNP and promotes chondrocyte growth in the cartilage plate by antagonizing MAPK signaling downstream of FGFR3 through cGMP production. Loss of NPR2 function blocks the CNP-NPR2-cGMP pathway, impairing growth of the distal cartilage plates. Heterozygotes may tend toward short stature, and homozygotes develop typical Maroteaux dysplasia.

In addition, various other subtypes such as DuPan syndrome (severe GDF5 variants, absence of distal limb parts), Fuhrmann syndrome, and AMDH (acromesomelic dysplasia, Hunter-Thompson type) may be included in the Q77.8 category.


3. Genetics

The BMPR1B gene is located on the long arm of chromosome 20 (20q13.2) and is a member of the BMP receptor family (type I). It binds BMP ligands (GDF5, BMP2, BMP4, BMP7, etc.) to activate the intracellular SMAD1/5/8 pathway and regulates chondrocyte differentiation and proliferation as well as joint formation. BMPR1B expression is high in the distal zone of the cartilage plate (distal growth plates of the tubular bones), making it especially important for growth in this region. The phenotype varies with the severity and location of BMPR1B variants: heterozygous variants cause brachydactyly (brachydactyly A1 or A2), and homozygous variants cause Grebe or Hunter-Thompson dysplasia.

The NPR2 gene is located on the short arm of chromosome 9 (9p21); as a membrane-bound guanylate cyclase, it produces cGMP upon CNP binding and inhibits the MAPK pathway. It is highly expressed in proliferating chondrocytes of the cartilage plate, and the CNP-NPR2-cGMP-MAPK inhibition axis promotes chondrocyte growth. Heterozygous NPR2 loss-of-function variants cause reduced height (part of the causes of idiopathic short stature), and homozygous variants cause Maroteaux dysplasia. Conversely, NPR2 gain-of-function variants cause overgrowth (tall stature).

The GDF5 gene is located on the long arm of chromosome 20 (20q11.2) and encodes a growth factor of the TGF-β superfamily that is broadly involved in joint formation, chondrocyte proliferation, and tendon/ligament development. Heterozygous GDF5 variants cause brachydactyly (brachydactyly C, symphalangism), and homozygous variants cause Hunter-Thompson or Grebe dysplasia. A GDF5 promoter polymorphism (rs143384) is associated with susceptibility to osteoarthritis, suggesting that the GDF5 pathway is broadly involved in joint health.

The mode of inheritance of the disorders in this category is mostly autosomal recessive, and frequency is high in consanguineous populations or closed populations with a founder effect. A comprehensive skeletal dysplasia NGS panel is the most efficient means of molecular genetic confirmation, and identifying the causative gene is essential for accurate subtype diagnosis and genetic counseling.


4. General epidemiology

The frequency of each disease subtype included in the Q77.8 category is individually very low; most are ultra-rare diseases at the level of 1 in several hundred thousand to several million births. Many subtypes have only tens to hundreds of patients reported in the worldwide literature.

The exact frequency of Maroteaux dysplasia, the most common subtype of acromesomelic dysplasia, is unknown, but it is very rare in the general population. Heterozygous NPR2 loss-of-function variants have been reported to explain some cases of idiopathic short stature, so diagnosis may be missed at the mild end of the subtype spectrum. Grebe dysplasia has been reported in a relatively large number of cases in a particular region of Brazil due to consanguinity, but is very rare worldwide.

Because of autosomal recessive inheritance, the risk increases when carrier parents are consanguineous or come from the same founder population. Males and females are affected equally, and it occurs sporadically in all ethnic groups worldwide. In Korea, the disorders in this category are ultra-rare diseases; very few patients are registered for Special Copayment Reduction (V228), and most are known only through individual case reports. As molecular genetic diagnosis advances, patients previously classified as having 'unspecified skeletal dysplasia' are increasingly being diagnosed with specific subtypes.


5. Pathophysiology

The pathophysiology of the Q77.8 category disorders differs by subtype, but commonly converges on abnormalities of the major signaling pathways that regulate proliferation and differentiation of cartilage plate chondrocytes.

BMP/GDF-BMPR1B pathway (Grebe, Hunter-Thompson dysplasia): normally, BMP-family growth factors (GDF5, BMP2, BMP4, etc.) bind to the BMPR1B and BMPR2 heterodimeric receptor, phosphorylate intracellular SMAD1/5/8, and promote chondrocyte differentiation and joint formation. GDF5-BMPR1B signaling is especially important in the distal limb growth plates, and during joint formation GDF5 regulates joint space formation and chondrocyte differentiation in the joint interzone. Loss of BMPR1B function blocks this signaling, so that chondrocyte proliferation in the distal limb cartilage plates is extremely reduced and abnormal joint formation accompanies it. As a result, the distal and middle segments of the fingers and toes are severely hypoplastic, producing the extreme distal limb shortening characteristic of Grebe dysplasia.

CNP-NPR2-cGMP pathway (Maroteaux dysplasia): the NPR2 (NPR-B) receptor has guanylate cyclase activity upon CNP binding and produces cGMP. Within the cell, cGMP inhibits the MEK-ERK (MAPK) pathway, weakening growth-inhibitory signals in chondrocytes and consequently promoting proliferation of cartilage plate chondrocytes. This is the mechanism by which CNP-NPR2-cGMP antagonizes the ERK pathway activated by FGFR3, and is the same as the principle of action of vosoritide (a CNP analog). When NPR2 function is lost, this antagonistic mechanism disappears, ERK signaling becomes relatively dominant, and growth of cartilage plate chondrocytes is suppressed. Interestingly, homozygous NPR2 loss of function causes a pathway abnormality similar to that of achondroplasia (FGFR3 overactivation)—reduced CNP signaling—so whether vosoritide exerts an effect through pathways other than NPR2 (increasing cGMP) is under investigation.

Abnormalities of both pathways act disproportionately strongly on the distal cartilage plates (growth plates of the distal limbs), producing an 'acromesomelic' or 'mesomelic' dwarfism pattern in which the distal limb segments are selectively shortened more.


6. Symptoms

Symptoms of the Q77.8 category disorders vary by subtype, but a common feature is selective shortening of specific limb segments.

Symptoms of Grebe dysplasia: characterized by extreme distal limb shortening, with short fingers and toes of the hands and feet (brachydactyly, especially of the middle and distal phalanges) and marked shortening of the distal long bones. The proximal limbs (upper arm, thigh) are relatively less affected. Adult height is relatively less reduced, but the distal limb deformities are severe and greatly limit function in daily living. Joint dysplasia and contractures are present, and joint fusion (synostosis) may also occur. Intelligence is normal.

Symptoms of Maroteaux dysplasia (AMDM): shortening of the distal and middle limb segments occurs, but is milder than in Grebe dysplasia. Shortening of the forearms and lower legs is pronounced, and the hands and feet are also short. The spine is relatively normal, but mild spinal abnormalities are present in some. Adult height is in the range of about 95–130 cm. Limited joint range of motion and chronic joint pain become problems in adulthood. Normal intelligence.

Common symptoms: the common symptoms of the disorders in this category are ① selective shortening of the distal or middle limb segments (in contrast to rhizomelia), ② short fingers and toes (brachydactyly), ③ joint dysplasia and contractures, ④ normal intelligence, and ⑤ spinal abnormalities (mild or absent depending on subtype). Congenital heart defects and ophthalmic abnormalities are not common in this category.


7. Signs

Physical signs: in Grebe dysplasia, the hands and feet are extremely short, and the fingers appear short like little fingers or absent. Multiple joint contractures are present, and joint dysplasia and stiffness are confirmed on palpation. Overall height may be mildly reduced. In Maroteaux dysplasia, shortening of the forearms and hands and of the lower legs and feet is pronounced and evident on physical examination. Mild spinal abnormalities may be found on palpation of the spine.

Radiographic signs: whole-body skeletal radiographs show findings characteristic of each subtype. Grebe dysplasia: extreme shortening of the distal long bones, shortening of the metacarpals and metatarsals, absent or small phalanges, joint dysplasia and fusion. Maroteaux dysplasia: shortening of the forearms (radius, ulna) and lower legs (tibia, fibula), brachydactyly of the hands and feet, mild or normal spinal findings. In both subtypes the proximal limbs (humerus, femur) are relatively less involved. Pelvic and cranial findings are generally normal, which helps in differentiation from achondroplasia.

Functional assessment: hand function assessment (pinching, grasping, etc.), gait analysis, and measurement of joint range of motion are important for determining functional level and planning treatment. The degree of chronic joint pain is quantified with tools such as a visual analog scale (VAS), and the impact on daily living is assessed with quality-of-life instruments.


8. Screening

Population-wide screening for the Q77.8 category disorders is not performed; systematic evaluation is carried out in high-risk groups and clinically suspected patients.

Prenatal ultrasound: if shortening of the distal limbs (forearms, lower legs, hands, feet), shortened fingers and toes, or joint contractures are observed on standard prenatal ultrasound, a skeletal dysplasia including acromesomelic dysplasia is suspected. If the proximal limbs (upper arm, thigh) are relatively normal, an acromesomelic or mesomelic dysplasia is more likely than achondroplasia. Detailed ultrasound at 20–24 weeks of gestation is especially important when the parents are carriers.

Molecular genetic prenatal diagnosis: in pregnancies of carrier couples (with confirmed variants in BMPR1B, NPR2, GDF5, etc.), fetal DNA is obtained by chorionic villus sampling or amniocentesis and analyzed for the relevant variant. When the familial variant is known, targeted variant analysis can yield results quickly.

Postnatal clinical screening: if selective shortening of the distal limbs is observed at birth, whole-body skeletal radiographs and NGS-based skeletal dysplasia panel analysis are performed. Because subtype differentiation is difficult from clinical findings alone, molecular genetic confirmation is essential for the final diagnosis.


9. Diagnosis

Diagnosis of the Q77.8 category disorders proceeds in steps: a skeletal dysplasia category is suspected from characteristic clinical and radiographic findings, and the specific subtype is confirmed by NGS-based molecular genetics.

Clinical diagnostic approach: acromesomelic dysplasia is suspected when there is a combination of selective shortening of the distal or middle limbs + short fingers and toes + joint dysplasia. Differentiation from achondroplasia (rhizomelic) is important, and the relatively lesser involvement of the proximal limbs is a distinguishing point. Other skeletal dysplasias are differentiated by the presence and degree of spinal abnormalities, ophthalmic abnormalities, and cranial findings.

Radiographic examination: on whole-body skeletal radiographs, the pattern of shortening of each limb segment, the shape of the phalanges, metacarpals, and metatarsals, joint dysplasia, and spinal findings are comprehensively evaluated. Because the characteristics of radiographic findings differ by subtype, collaboration between radiologists and skeletal dysplasia specialists is important.

Molecular genetic confirmation: NGS-based skeletal dysplasia panel (including BMPR1B, NPR2, GDF5, BMPR2, etc.) or single-gene analysis according to clinical suspicion. Identification of a variant confirms the subtype diagnosis. If no variant is identified, whole-exome sequencing (WES) or whole-genome sequencing (WGS) is considered.

Differential diagnosis: achondroplasia (FGFR3, rhizomelic), diastrophic dysplasia (SLC26A2, prominent joint contractures), isolated brachydactyly (heterozygous GDF5, BMPR1B — mild), mesomelic dwarfism (other etiologic groups).


10. Treatment

There is currently no curative treatment for the Q77.8 category disorders; treatment aims to improve function and manage complications.

Limb function and orthoses: when there is severe distal limb shortening and joint contractures, daily function and independence are maximized through orthotic devices, customized handles, and assistive technology. Occupational therapists play an important role in prescribing and training in the use of aids for daily living.

Correction of joint contractures: mild contractures are managed with physical therapy and night splints. For severe contractures, soft tissue release or osteotomy may be considered. When joint dysplasia is severe, surgical correction is needed to maintain function.

Pain management: for chronic joint pain in adulthood, acetaminophen, COX-2 inhibitors, physical therapy, aquatic exercise, and psychological pain management strategies are used. When early degenerative arthritis progresses, joint replacement is considered.

Potential targeted therapy for the NPR2-related type: because the mechanism of Maroteaux dysplasia (NPR2 loss of function) is an abnormality of the CNP-NPR2 pathway, a treatment approach through NPR2 activation is theoretically possible. However, research is ongoing on the effect of methods that increase cGMP without going through NPR2 (e.g., PDE inhibitors) in patients with NPR2 loss of function, and since vosoritide (a CNP analog) has no effect if NPR2 does not function, a different approach is needed.

Psychosocial support: counseling and support for psychological difficulties due to abnormal appearance and functional limitation are important. Linking with patient organizations and support groups helps improve quality of life.


11. Prognosis

Life expectancy in the Q77.8 category disorders is generally normal, and intelligence is also normal. The main prognostic determinants are the degree of limb functional limitation and chronic pain.

Functional prognosis: in Grebe dysplasia, hand function is very limited due to extreme distal limb shortening and joint dysplasia, and assistance with daily living is often needed. Walking is possible, but special footwear is needed because of distal foot dysplasia. In Maroteaux dysplasia, functional limitations are milder, and many patients carry out daily living and occupational activities independently.

Joint complications: when joint dysplasia is present, early degenerative arthritis develops in adulthood and is the main cause of chronic pain and functional decline. Regular joint assessment, weight management, and appropriate physical therapy can slow the progression of joint complications.

Quality of life: in addition to physical functional limitations, body image, social prejudice, and limited career choices can affect quality of life. Psychological counseling, participation in patient organizations, and social support networks help psychosocial adjustment.

Monitoring: regular orthopedic evaluation (joint function, spinal abnormalities, progression of arthritis) and pain assessment are recommended into adulthood. When surgical treatment such as joint replacement is needed, it is recommended that it be performed by a surgical team experienced with skeletal dysplasia patients.


12. Prevention

Primary prevention — genetic counseling and genetic testing: when affected patients or carrier parents are planning children, genetic counseling is used to discuss the recurrence risk (25% for carrier couples) and options of preimplantation genetic testing (PGT) and prenatal diagnosis. Because of autosomal recessive inheritance, there is a 25% recurrence risk with each pregnancy of a carrier couple, so when a familial variant has been identified, affected embryos can be selected in advance through prenatal molecular genetic analysis or PGT.

Secondary prevention — early detection and treatment of complications: the subtype is accurately diagnosed immediately after birth by whole-body skeletal radiographs and NGS confirmation, and a regular evaluation plan is established according to the list of anticipated complications for each subtype. Early physical and occupational therapy to maintain joint function and prescription of orthoses improve the functional prognosis.

Tertiary prevention — maintaining quality of life: minimize joint loading through weight management; recommend low-impact exercise (swimming, cycling); maximize independence through assistive technology and environmental modification; regular orthopedic and pain management follow-up; maintain overall quality of life through psychosocial support and linking with patient organizations.


13. References

  1. Maroteaux P, Martinelli B, Campailla E. Le nanisme acromésomélique. Presse Med. 1971;79(20):1839-1842. PMID: 5556659.

  2. Thomas JT, Lin K, Nandedkar M, et al. A human chondrodysplasia due to a mutation in a TGF-beta superfamily member. Nat Genet. 1996;12(3):315-317. DOI: 10.1038/ng0396-315. PMID: 8589725.

  3. Bartels CF, Bukulmez H, Padayatti P, et al. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet. 2004;75(1):27-34. DOI: 10.1086/422013. PMID: 15148656.

  4. Demirhan O, Türkmen S, Schwabe GC, et al. A homozygous BMPR1B mutation causes a new subtype of acromesomelic chondrodysplasia with genital anomalies. J Med Genet. 2005;42(4):314-317. DOI: 10.1136/jmg.2004.023564. PMID: 15805161.

  5. Vasques GA, Amano N, Docko AJ, et al. Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a cause of short stature in patients initially classified as idiopathic short stature. J Clin Endocrinol Metab. 2013;98(10):E1636-1644. DOI: 10.1210/jc.2013-2142. PMID: 23979952.

  6. Olney RC, Prickett TC, Espiner EA, et al. C-type natriuretic peptide and bone growth: current concepts and future directions. Pediatr Nephrol. 2015;30(7):1111-1120. DOI: 10.1007/s00467-014-2931-3. PMID: 25199569.

  7. Thomas JT, Kilpatrick MW, Lin K, et al. Disruption of human limb morphogenesis by a dominant negative mutation in CDMP1. Nat Genet. 1997;17(1):58-64. DOI: 10.1038/ng0997-58. PMID: 9288098.

  8. Bonafe L, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A. 2015;167A(12):2869-2892. DOI: 10.1002/ajmg.a.37365. PMID: 26394607.

  9. Kuchenbecker J, Schneider EM, Semler O, et al. Acromesomelic dysplasia: a comprehensive review. Orphanet J Rare Dis. 2023;18(1):14. DOI: 10.1186/s13023-023-02613-7. PMID: 36658546.

  10. Mundlos S. The brachydactylies: a molecular disease family. Clin Genet. 2009;76(2):123-136. DOI: 10.1111/j.1399-0004.2009.01238.x. PMID: 19780763.